Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 12:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2017–2040 of 4,023 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 3 Clear all

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Triple-Negative Breast Carcinoma, Metastatic Urothelial Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions: Atezolizumab, Cyclophosphamide, Fludarabine, MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells, PD1 Inhibitor; Drug · Biological
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Prostate Cancer
Interventions: Exercise Program, Diet and Nutrition Coaching, Usual Care with Attention; Behavioral · Other
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 21 Years and older · Male only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 2
States / cities: Los Angeles, California • Kansas City, Kansas

Conditions: Malaria Falciparum, Malaria Vivax, Healthy Volunteers
Interventions: OZ439 50mg API capsules, OZ439 200mg API capsules, OZ439 400mg aqueous dispersion, OZ439 800mg aqueous dispersion, OZ439 100mg API capsules, OZ439 400mg API capsules, OZ439 1600mg aqueous dispersion, OZ439 800mg API capsules, OZ439 1200mg API capsules, Placebo, OZ439 200mg aqueous dispersion; Drug
Lead sponsor: Medicines for Malaria Venture; Other
Eligibility: 18 Years to 55 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Heterozygous Familial Hypercholesterolemia (HeFH)
Interventions: Enlicitide Decanoate, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2037
U.S. locations: 8
States / cities: Wilmington, Delaware • Washington D.C., District of Columbia • Boca Raton, Florida + 5 more

Conditions: Neoplasms
Interventions: feladilimab, Tremelimumab, Docetaxel, Paclitaxel, Cetuximab; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 5
States / cities: Boston, Massachusetts • New York, New York • Pittsburgh, Pennsylvania + 1 more

Conditions: Solid Tumor
Interventions: SMP3124LP; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 11
States / cities: Los Angeles, California • San Francisco, California • Denver, Colorado + 6 more

Conditions: Locally Advanced/Metastatic Solid Tumors
Interventions: BJ-001, Pembrolizumab; Drug
Lead sponsor: BJ Bioscience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 5
States / cities: St Louis, Missouri • New York, New York • Greenville, South Carolina + 2 more

Conditions: Covid19
Interventions: Filtration Fan, Safe-home pamphlet, Mid-week phone call; Device · Behavioral
Lead sponsor: Stanford University; Other
Eligibility: Not listed
Enrollment: 214 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: San Mateo, California • Stanford, California

Conditions: Glioblastoma Multiforme
Interventions: Support Vector Machine; Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Knee Osteoarthristis, ACL Injuries, Post-Traumatic
Interventions: extracorporeal shockwave therapy (ESWT), Sham Comparator; Device
Lead sponsor: Spaulding Rehabilitation Hospital; Other
Eligibility: 18 Years to 55 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Solid Tumors Harboring NTRK Fusion
Interventions: Selitrectinib (BAY2731954) Adult tablet, Selitrectinib (BAY2731954) Pediatric tablet, Selitrectinib (BAY2731954) Oral solution, Selitrectinib (BAY2731954) Oral suspension; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 2
States / cities: Glendale, California • Baltimore, Maryland

Conditions: Type 2 Diabetes, Type 1 Diabetes, Pregnancy, High Risk
Interventions: Mid-Ohio Food Farmacy (MOF+) produce delivery, Nutrition education with Dining with Diabetes (DWD), Health Impact Ohio Central Ohio Pathways Hub to address unmet social needs; Dietary Supplement · Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Neurogenic Bladder, Multiple Sclerosis, Voiding Dysfunction
Interventions: Transcranial Rotating Permanent Magnet Stimulator (TRPMS); Device
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years to 80 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: ccRCC, RCC, Kidney Cancer, Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma
Interventions: MK-3795, Nivolumab, Cabozantinib, Bezlutifan; Drug
Lead sponsor: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 25
States / cities: Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 18 more

Conditions: Malignant Melanoma
Interventions: CMP-001, Pembrolizumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 4
States / cities: Los Angeles, California • Aurora, Colorado • Iowa City, Iowa + 1 more

Conditions: Advanced Solid Tumors
Interventions: Alisertib; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Well Being
Interventions: Community of Voices choir program, Wait-list control group; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 60 Years and older
Enrollment: 390 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Prostate Cancer
Interventions: Prednisone, Apalutamide, Abiraterone Acetate, LHRH Agonist or Antagonist; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 5
States / cities: Boston, Massachusetts • Milford, Massachusetts • South Weymouth, Massachusetts

Conditions: Breast Cancer
Interventions: BB-1701; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 27
States / cities: Los Alamitos, California • Los Angeles, California • San Francisco, California + 22 more

Conditions: Bipolar Disorder, Major Depressive Disorder, Menopause
Interventions: Cognitive Behavioral Group Therapy; Behavioral
Lead sponsor: Danette Conklin, PhD; Other
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Obesity, Overweight, Quality of Life
Interventions: The iDiet® (also called Healthy Weight for Living when used as a not-for-profit intervention) with Food, The iDiet® (also called Healthy Weight for Living when used as a not-for-profit intervention) with Voucher, Human Performance Institute©; Behavioral
Lead sponsor: Tufts University; Other
Eligibility: 21 Years and older
Enrollment: 554 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Essential Tremor
Interventions: 60 mg ulixacaltamide, Placebo; Drug
Lead sponsor: Praxis Precision Medicines; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Non-Small Cell Lung Cancer, NSCLC, Advanced Non-Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
Interventions: Reduced Dose of Chemotherapy and Immunotherapy; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 2
States / cities: Richmond, Virginia • Tappahannock, Virginia

Conditions: Hair Thinning
Interventions: Active Comparator- Xtressé™ Supplement and Serum, Placebo Comparator- Placebo Supplement and Serum; Dietary Supplement
Lead sponsor: The Center for Clinical and Cosmetic Research; Other
Eligibility: 28 Years to 65 Years · Female only
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Birmingham, Alabama • Aventura, Florida

Search by objective public record fields.

Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer

Staying Strong and Healthy During Androgen Deprivation Therapy (ADT) for Men

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of OZ439 in Healthy Male and Female Subjects

A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)

GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors

SMP-3124LP in Adults With Advanced Solid Tumors

Safety Study of BJ-001, an IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors

Cluster-Randomized Trial of Air Filtration and Ventilation to Reduce Covid19 Spread in Homes

Neurosurgical Neuronavigation Using Resting State MRI and Machine Learning

Treatment of Post Traumatic Knee Osteoarthritis With Extracorporeal Shockwave Therapy

Study to Compare How the Body Absorbs, Distributes and Excretes the Drug Selitrectinib (BAY2731954) Given as Two Different Tablet Formulations or as Liquid Formulations Including the Effect of Food on the Absorption, Distribution or Excretion of the Different Formulations in Healthy Participants

NOURISH - A Healthcare-community Partnership to Improve Nutrition for Optimal Glycemic Control and Pregnancy Outcomes With Pregestational Diabetes

Brain Targets in Patients With Bladder Emptying Difficulties

A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)

Phase 1B Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Participants With Advanced Melanoma

Study of MLN8237 in Participants With Advanced Solid Tumors

Community Choirs To Promote Healthy Aging; Community of Voices Chorus

Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT

A Study of BB-1701 in Previously Treated Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive or HER2-low Unresectable or Metastatic Breast Cancer

Cognitive Behavioral Group Therapy for the Management of Menopause Symptoms in Mood Disorders

Worksite Wellness Randomized Controlled Trial

Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in Essential Tremor (ET)

Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)

Evaluating the Combined Use of Supplement and Serum in Promoting Hair Growth in Women With Self-perceived Thinning Hair